Table 1.
Clinical outcome in selected prospective trials on SBRT for cT1-2N0M0 NSCLC.
| Study | N | Dose | Patterns of Failure | Survival |
|---|---|---|---|---|
| Nordic phase II study [6] | 57 | 45 Gy/3 Frx | 3 yr Estimates: Local control: 92%; all failures are T2; Any failure: (T2 vs. T1 p = 0.027) T2a = 40.8%; T1b = 25.4%; T1a = 0.0% |
3 yr Estimates: PFS: 52% OS: 60% CSS: 88% |
| RTOG 0236 [7,8] | 55 | 54 Gy/3 Frx | 3 yr Estimates: Local control: 97.6%; 1 failure, T2 Lobar control: 90.6% Local-regional control: 87.2% DM: 22.1% (T1: 14.7%; T2: 47%) 5 yr Estimates: Local control: 92.7% Lobar control: 80% Local-regional control: 74.5% DM: 23.6% (T1: 18.2%; T2: 45.5%) |
3 yr Estimates: DFS: 48.3% OS: 55.8% 5 yr Estimates: DFS: 25.5% OS: 40.0% |
| MISSILE-NSCLC trial [9] | 35 | 54 Gy/3 Frx 55 Gy/5 Frx 60 Gy/8 Frx |
pCR: 60% 2 yr Estimates (surgery group): Local control: 100% Regional control: 53% DM: 24% |
2 yr OS: 77% |
| RTOG 0915 [10] | 39 and 45 | 34 Gy/1 Frx and 48 Gy/4 Frx |
2 yr Estimates: Local control: 97.4% and 97.8% |
2 yr Estimates: DFS: 56.4% and 71.1% OS: 61.3% and 77.7% |
| RTOG 0813 [11] | 38 and 33 | 57.5 Gy/5 Frx and 60 Gy/5 Frx |
3 yr Estimates: Lobar control: 86.7% and 84.7% |
3 yr Estimates: PFS: 35.7% and 32.5% OS: 51.6% and 54.0% |
Frx: fractions; yr: year; PFS: progression-free survival; OS: overall survival; CSS: cancer-specific survival; DFS: disease-free sur vival; DM: distant metastases; pCR: pathological complete response.